This abstract was presented at the 7th Annual Health Technology Assessment International (HTAi) Conference in Dublin in June 2010 (http://www.htai2010.org/site/).
Article: Health Economics
The cost of universal screening for gestational diabetes mellitus in Ireland
Version of Record online: 13 JUL 2011
© 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK
Volume 28, Issue 8, pages 912–918, August 2011
How to Cite
Gillespie, P., O’Neill, C., Avalos, G., O’Reilly, M., Dunne, F. and for the ATLANTIC DIP Collaborators (2011), The cost of universal screening for gestational diabetes mellitus in Ireland. Diabetic Medicine, 28: 912–918. doi: 10.1111/j.1464-5491.2011.03293.x
- Issue online: 13 JUL 2011
- Version of Record online: 13 JUL 2011
- Accepted manuscript online: 18 MAR 2011 10:03AM EST
- Accepted 4 March 2011
Vol. 33, Issue 5, 701, Version of Record online: 18 APR 2016
- cost analysis;
- gestational diabetes mellitus
Diabet. Med. 28, 912–918 (2011)
Aims To estimate the costs associated with universal screening for gestational diabetes mellitus in Ireland.
Methods Bottom-up, prevalence-based cost analysis. Healthcare activity identified using the Atlantic Diabetes in Pregnancy (ATLANTIC DIP) database was grouped into five categories: screening and testing, gestational diabetes treatment, prenatal care, delivery care and neonatal care. A vector of unit cost data (euros in 2008 prices) was applied to specified resource use and the total healthcare cost calculated. A series of one-way and probabilistic sensitivity analyses were undertaken to explore the uncertainty in the analysis.
Results When individual resource components were valued and aggregated, the total healthcare cost of gestational diabetes in Ireland was estimated at €12 433 320 (95% CI €9 298 228–16 778 193). The average cost per case detected was €1621 (95% CI €524–2603) and the average total cost per case detected and treated was €11 903 (95% CI €7645–16 121).
Conclusions This research provides the first estimates of the healthcare costs associated with gestational diabetes mellitus in Ireland. Further research is required to determine the cost-effectiveness of gestational diabetes screening in the region with a view to improving resource allocation in this area in the future.